Your essential biotech, medtech, and pharma recap — no noise, just what matters.

Three stories from the weekend reshape their respective markets. First, the Supreme Court's mifepristone ruling resolves the near-term regulatory uncertainty we have been tracking since the 5th Circuit decision on May 1. Access is preserved while litigation continues. The precedent question, whether courts can override FDA dispensing decisions, remains unresolved on the merits, but the immediate disruption is over. Second, Enhertu's approval in early breast cancer is a landmark for the ADC modality. ADCs have been transforming metastatic oncology for years, but this approval brings the modality into the curative (early-stage) setting for breast cancer. The DESTINY-Breast11 and Breast05 data established Enhertu's role both before and after surgery. For Daiichi Sankyo, which just announced a $14.6B oncology revenue target by 2030, this is the kind of label expansion that moves the franchise toward that goal. For Gilead's $5B Tubulis acquisition and the broader ADC pipeline, it validates that the modality can extend beyond late-stage disease. Third, the Tecentriq/Signatera approval is the diagnostics story we have been waiting for. Natera's ctDNA-based MRD test is now an FDA-approved companion diagnostic for a checkpoint inhibitor, creating a template for biomarker-driven treatment decisions in adjuvant oncology. This is the most concrete commercial validation of liquid biopsy technology in 2026. 👉 Read Full Analysis

Supreme Court Preserves Mifepristone Access

The Supreme Court ruled to maintain access to mifepristone while litigation continues, according to BioPharma Dive. The drug can still be prescribed at pharmacies or by mail without requiring in-person visits. The 5th Circuit's May 1 ruling reinstating nationwide in-person dispensing requirements remains blocked. This resolves the immediate access disruption we have tracked since Alito's administrative stay on May 4. The underlying legal question, whether federal courts can override FDA dispensing decisions, remains unresolved and could return to the Court on the merits.

Enhertu Approved for Early Breast Cancer in Landmark ADC Expansion AZN | DSNKY

The FDA approved Enhertu (trastuzumab deruxtecan) on May 16 for both neoadjuvant and adjuvant treatment of HER2-positive early breast cancer, based on the Phase 3 DESTINY-Breast11 (neoadjuvant) and DESTINY-Breast05 (adjuvant) trials. This marks a landmark expansion of the ADC modality into the early (curative-intent) breast cancer setting. The approval significantly expands Enhertu's addressable market from metastatic disease to the much larger early-stage population. Enhertu is co-developed by AstraZeneca and Daiichi Sankyo and is already the world's leading ADC franchise.

Foundayo Maintenance Data Support Long-Term Dosing Strategy LLY

BioSpace reported that patients in two trials maintained most of their weight loss after switching to either Foundayo or lower-dose Zepbound from other injectable incretin therapies. Lilly is positioning Foundayo as part of a long-term obesity care strategy, with data suggesting patients can sustain weight loss on maintenance doses rather than requiring continuous high-dose therapy. This addresses a key concern in the GLP-1 market: the approximately 65% one-year discontinuation rate observed across the class.

Tecentriq Label Expansion with Natera Signatera Companion Diagnostic RHHBY | NTRA

The FDA approved a Tecentriq (atezolizumab) label expansion on May 15 alongside Natera's Signatera as a companion diagnostic, according to Fierce Pharma. Signatera uses circulating tumor DNA (ctDNA) analysis to detect minimal residual disease (MRD) after surgery, identifying patients who may benefit from adjuvant immunotherapy. This is one of the most significant regulatory validations of liquid biopsy technology in oncology. For Natera, the companion diagnostic approval creates a clear reimbursement pathway and commercial anchor for Signatera beyond its existing laboratory-developed test revenue. For the diagnostics industry, it establishes a template for integrating ctDNA-based MRD testing into treatment algorithms for checkpoint inhibitors.

Anthropic Partners with Gates Foundation on Global Health AI

Anthropic announced a four-year partnership with the Gates Foundation focused on vaccines, disease modeling, and health-system operations in lower-income countries, according to The Pharma Letter. The partnership builds on Anthropic's expanding life sciences footprint, which now includes the $400M Coefficient Bio acquisition (April), Novartis CEO Narasimhan's board appointment (April), and existing partnerships with Sanofi, Novo Nordisk, and AbbVie. This is the first Anthropic partnership focused on global health rather than pharmaceutical R&D, broadening the company's healthcare positioning.

China's Decree No. 834 Threatens Western Pharma Operations

STAT reported that China issued Decree No. 834 on April 7, the Regulations on Industrial and Supply Chain Security, giving Beijing sweeping new powers to investigate and sanction foreign companies whose commercial decisions are deemed to harm China's industrial chain security. China's 15th five-year plan explicitly designates biotechnology and pharmaceuticals as the centerpiece of its next industrial development phase. The decree has direct implications for Western pharma companies with Chinese partnerships (BMS/Hengrui, Lilly/Hengrui via Kailera, AbbVie/Haisco, GSK/SiranBio) and manufacturing operations.

👉 Read Full Analysis

Enhertu's early breast cancer approval is a category-defining moment for the ADC modality. Until now, ADCs have been approved almost exclusively in the metastatic (incurable) setting, where they extend survival but rarely cure disease. Moving into neoadjuvant and adjuvant treatment means ADCs are now being used with curative intent, in patients whose cancers can potentially be eliminated entirely.

The implications extend beyond Enhertu. Gilead's $5B Tubulis acquisition and $7.8B Arcellx deal, Lilly's $300M CrossBridge acquisition, and the dozens of ADC programs in clinical development all gain validation from this approval. If ADCs work in early breast cancer, the modality will be tested in early-stage lung cancer, colorectal cancer, gastric cancer, and other solid tumors. Each early-stage label expansion dramatically increases the addressable patient population relative to the metastatic setting.

For Daiichi Sankyo, this approval is the most important step toward its $14.6B oncology revenue target by 2030. Enhertu's metastatic breast cancer and lung cancer indications generate significant revenue. Adding early breast cancer, where the patient volume is substantially larger, could push the drug toward true mega-blockbuster status.

💊 Signatera: The Liquid Biopsy Template

Natera's Signatera has been used as a laboratory-developed test for several years. The companion diagnostic approval with Tecentriq elevates it to a fundamentally different commercial position. Now Signatera is an FDA-approved part of the treatment algorithm: patients test positive for ctDNA after surgery, and the test result directly informs the decision to prescribe Tecentriq.

This creates a reimbursement pathway that is cleaner than the laboratory-developed test model. It also creates a template that other checkpoint inhibitor manufacturers (Merck/Keytruda, BMS/Opdivo) will want to replicate with their own companion diagnostic partnerships. If Signatera or competing ctDNA platforms become standard companion diagnostics across multiple checkpoint inhibitors, the addressable market for liquid biopsy in adjuvant oncology could exceed several billion dollars.

For the diagnostics sector, which we have covered lightly in this series, this is the story that matters most in 2026. Watch for additional companion diagnostic filings from Natera and competitors (Guardant Health, Foundation Medicine, Exact Sciences).

📊 China Decree 834: The New Regulatory Risk

Decree No. 834 gives Beijing authority to investigate foreign companies whose commercial decisions "harm China's industrial chain security." The definition of "harm" is broad and deliberately vague.

For Western pharma companies with Chinese partnerships, the risk is that China could use this decree to pressure companies into maintaining or expanding their Chinese operations, even when geopolitical considerations (BIOSECURE Act, Section 232 tariffs) push in the opposite direction. Companies most exposed include those with significant China licensing deals (BMS/Hengrui $15.2B, Lilly/Hengrui via Kailera, AbbVie/Haisco, GSK/SiranBio) and those with Chinese manufacturing dependencies.

The decree does not create immediate disruption. But it adds a new variable to the geopolitical calculus that every BD team and board of directors must now factor into China-related decisions.

🎯 Catalyst Calendar: May 2026 Forward

👉 Visit The Pro Hub

Limited ASCO-week sponsorship slots available (May 29 - June 2). Reach 65,000+ professionals during the biggest oncology event of the year. Learn more →

Is your company listed in the BioMed Nexus directory? 2,104 companies across 14 categories. Claim or upgrade your listing →

Sponsorship slots for 2026 are limited. See packages and pricing →

NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →